Recipharm AB (publ) (RCPHF) Stock Price, News & Analysis

Company Overview

Recipharm AB (publ) is a Sweden‐based contract development and manufacturing organization (CDMO) specializing in the pharmaceutical and biotechnology sectors. The company offers end‐to‐end services spanning drug product development, clinical trial material supply and commercial manufacturing. Its service portfolio encompasses small‐molecule active pharmaceutical ingredients (APIs), sterile fill‐finish operations, inhalation products, solid dose formulations and specialized packaging solutions.

Recipharm operates a network of manufacturing facilities across Europe, North America and Asia Pacific, enabling flexible capacity and regional supply chain resilience. The company’s offerings include analytical and microbiological testing, formulation development, process optimization and regulatory support. By integrating development activities with large‐scale production, Recipharm aims to accelerate time to market and ensure quality standards are met from early‐phase trials through full commercial launch.

Founded in 1995 and headquartered in Stockholm, Sweden, Recipharm has grown through organic expansion and strategic acquisitions, broadening its geographical reach and technical capabilities. The company serves multinational pharmaceutical companies as well as emerging biotech firms, supporting projects in therapeutic areas such as oncology, respiratory care, hormones and orphan indications. Key leadership includes an executive team with experience in pharmaceutical operations, quality assurance and global project management.

Recipharm’s business model focuses on long‐term partnerships, leveraging its scientific expertise and manufacturing footprint to provide tailored solutions. The company continues to invest in facility upgrades, digital process controls and sustainable practices, positioning itself as a partner of choice for customers seeking reliable, compliant and cost‐effective contract manufacturing and development services.

Key Stats

• Today's Range: $16.05 to $16.05
• 50-Day Range: $16.05 to $16.05
• 52-Week Range: $16.05 to $17.41
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RCPHF Stock Analysis - Frequently Asked Questions

How have RCPHF shares performed this year?

Recipharm AB (publ)'s stock was trading at $16.05 on January 1st, 2025. Since then, RCPHF stock has increased by 0.0% and is now trading at $16.05.

How do I buy shares of Recipharm AB (publ)?

Shares of RCPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RCPHF
• CIK: N/A
• Web: www.recipharm.com
• Phone: 46 86 02 52 00
• Fax: N/A
• Employees: 7,383
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A